Pegfilgrastim biosimilar - Pfenex

Drug Profile

Pegfilgrastim biosimilar - Pfenex

Alternative Names: PF-529

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfenex - Stelis Biopharma (JV)
  • Developer Pfenex
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neutropenia

Most Recent Events

  • 28 Jul 2016 Pegaspargase licensed to Jazz Pharmaceuticals worldwide
  • 16 Mar 2015 Pfenex terminates its agreement with Stelis Biopharma for Neutropenia
  • 30 Jun 2014 Preclinical trials in Neutropenia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top